P lasma lipid concentrations are heritable therapeutic intervention targets for cardiovascular disease 1,2 . Meta-analysis of 23 studies of 94,595 individuals with genome-wide genotype data and 93,982 individuals with Metabochip genotype data in the Global Lipids Genetics Consortium (GLGC) identified 157 loci associated with plasma concentrations of HDL, LDL, triglycerides, and total cholesterol 3 , extending the findings in ref. 4 . Subsequent studies found additional associations [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , totaling approximately 189 loci, plus two founder variants common only in Sardinians 19 .
medications (Methods). Of the 46 SNPs, 17 replicated at a Bonferronicorrected significance level (P < 0.05/46 = 0.0011) and 14 additional SNPs were nominally significant (P < 0.05); there was a clear distributional enrichment for smaller P values: for example, 67% of the SNPs had nominal significance or better, far more than the 2.5% expected by chance (requiring the same direction of effect; Supplementary Fig. 4 ). Seven of the 46 SNPs reached genome-wide significance for multiple traits. None of the 46 SNPs had significant heterogeneity of effect 34 within GERA (Bonferroni-corrected P < 0.0011; Table 2 ).
We suspect that our new hits were generally not previously identified because of insufficient power; most are near the genomewide significance threshold, with two exceptions. One exception, rs306890 (GERA P = 1.1 × 10 −22 ), is in the X-chromosome pseudoautosomal region, which is not as generally studied. Second, rs112545201 had P HDL = 2.5 × 10 −19 in GERA. It is possible that this association was missed owing to coverage and the imputation quality of previous arrays. We further enhanced discovery by GERA + GLGC meta-analysis (λ = 1.07-1.10); 60 additional new loci reached genome-wide significance for at least one lipid trait ( Table 2 and Supplementary  Tables 6 and 7) . Testing replication (including the same direction of effect) in UKB, 14 of these loci met Bonferroni-corrected significance (P < 0.05/60 = 0.00083) and 18 additional loci were nominally significant (P < 0.05). Replication was much stronger for SNPs with LDL as the lead trait: 36% and 91% of LDL-associated SNPs met Bonferroni-corrected and nominal significance, respectively, with 16% and 42% for total cholesterol, 21% and 47% for triglycerides, and 22% and 50% for HDL. Nine loci reached genome-wide significance for multiple traits. None of the 60 SNPs had significant heterogeneity of effect among the GERA groups and GLGC (Bonferroni P < 0.00083; Table 3 ).
Replication of previously identified SNPs.
We tested all previously identified lipid-associated SNPs (at the time of this analysis) for replication in GERA [3] [4] [5] [11] [12] [13] [14] 16, 17 (Supplementary Table 4 ). Focusing on 189 available lead SNPs, 133 (70.4%) were significantly associated with the same previously identified lead trait (Bonferroni P < 0.00026) and 165 (87.3%) were nominally significant (P < 0.05; Fig. 1b ). The strongest predictor of replication was the original P value; for example, nearly all (40/41) SNPs with P < 1 × 10 −10 in GLGC replicated at a Bonferroni-corrected significance level. Four SNPs (2.2%) showed significant heterogeneity in effect among GERA groups and/ or GLGC (P < 0.00026; Supplementary Fig. 5 and Supplementary  Table 4 ). Seventy-two previously identified lead SNPs were genomewide significant (using GERA P values) for more than one trait.
Conditional analyses.
We conducted conditional analyses within the single large GERA cohort on each previously described or new GERA locus (Methods). Thirty-three loci contained 74 genomewide significant conditional variants (stepwise regression; Methods and Supplementary Tables 8 and 9 ). To determine whether these conditional SNPs were new, we tested each while conditioning on all previously identified SNPs and all SNPs from previous steps at that locus; 15 remained genome-wide significant ( Table 4 ). All had r 2 ≤ 0.1 with all previously identified SNPs.
Dominance. We tested the previously and newly identified lead and conditional SNPs for dominance effects in GERA non-Hispanic whites. Quantile-quantile plots showed moderate deviation from a null distribution for LDL (λ = 1.54) and total cholesterol (λ = 1.30), and little to no deviation for HDL (λ = 1.15) and triglycerides (λ = 1.02) ( Supplementary Fig. 6 ), with a few extreme outliers for each trait that were Bonferroni significant: rs1730859 (PRMT6 expression quantitative trait locus (eQTL), P LDL = 2.9 × 10 −4 ), rs1800562 (HFE missense mutation for hemochromatosis, p.Cys282Tyr, P LDL = 3.7 × 10 −6 , P total cholesterol = 1.6 × 10 −5 ), rs2519093 (ABO eQTL, P LDL = 7.5 × 10 −5 ), rs1800588 (LIPC eQTL, P HDL = 1.0 × 10 −6 ), rs7412 (APOE ϵ 2 allele, P total cholesterol = 3.7 × 10 −6 , P triglycerides = 1.8 × 10 −8 ), rs3764261 (CETP eQTL, P HDL = 3.7 × 10 −4 ), rs261334 (LIPC eQTL, P HDL = 5.1 × 10 −6 ), rs58542926 (TM6SF2 p.Glu167Lys, P LDL = 4.0 × 10 −11 , P total cholesterol = 8.8 × 10 −13 ), and rs492602 (FUT2 variant described below, P LDL = 0.00080). The APOE ϵ 2 dominance effect is due to very high triglyceride values among homozygotes for the ϵ 2 allele, likely resulting from type 3 hyperlipoproteinemia 35 identified lead and conditional SNPs. Overall, quantile-quantile plots showed no particular distributional deviation from expectation (λ < 1.04 for each trait; Supplementary Fig. 7) , with the exception of a few extreme data points for LDL. After Bonferroni correction, one SNP pair was significant, representing the interaction of rs2519093 (ABO) and rs492602 (FUT2; P LDL = 8.1 × 10 −10 , P total cholesterol = 3.9 × 10 −7 ; Fig. 1 and Supplementary Fig. 8 ), both of which showed dominance effects. SNP rs492602 has r 2 = 0.992 with rs601338, a nonsense dominant variant that determines FUT2 non-secretor status. The mean covariateadjusted residual LDL levels of the nine possible genotype combinations at the two SNPs showed that secretors had lower LDL than non-secretors; rs2519093 was statistically significantly associated with LDL among secretors (dominant model P = 5.5 × 10 −75 , β = 0.132, 95% confidence interval (CI) = 0.118-0.146), but almost not at all among non-secretors (dominant P = 0.038, β = 0.030, 95% CI = 0.002-0.058). We then examined SNP associations with LDL around rs2519093 among secretors only ( Fig. 1 and Supplementary Table 10 ). The high LD in the region made identification of the causal variant(s) difficult; haplotype fine-mapping was suggestive for rs635634 ( Supplementary  Table 11 ), the most significant regional SNP (P = 1.6 × 10 −76 ).
Sex and ancestry effects. We investigated sex differences in SNP effects (heterogeneity test, Supplementary Table 12 ; coefficient comparison, Supplementary Fig. 9 ). The quantile-quantile plot of the lead and conditional SNPs showed strong heterogeneity evidence for each trait (1.64 ≤ λ ≤ 2.44; Supplementary Fig. 10 ). After Bonferroni correction, seven lead SNPs were significantly different between the sexes in non-Hispanic whites at the lead trait, with six having stronger effects in women and one having a stronger effect in men (Supplementary Table 12 ). Five of the six significant conditional SNPs had stronger effects in women ( Supplementary Table 12 ). Similar relationships were previously observed near three of these loci: KLF14 and APOE, with stronger effects in women 4 , and ZNF259, with a stronger effect in men 36 .
Overall, 64% of HDL-associated, 64% of LDL-associated, and 56% of total cholesterol-associated SNPs showed stronger effects in women, while 66% of triglyceride-associated SNPs showed stronger effects in men. Quantile-quantile plots showed further distributional differences ( Supplementary Fig. 11 ). Pronounced differences were observed for HDL in Latino females (both directions) and East Asian females for HDL and triglycerides (effects greater in East Asians). Moderate differences were seen for triglycerides in Latino males (effects greater in Latinos) and for total cholesterol in African American females (effects greater in African Americans).
We then investigated mean differences in genetic risk scores (GRSs) constructed using all previously and newly identified lead and conditional SNPs (GERA meta-analysis weights, SNPs with pairwise r 2 > 0.3 excluded). All GRSs were significantly different between the sexes (P < 1 × 10 −200 ) and between all ancestry groups (P < 1 × 10 −8 ) except non-Hispanic white versus East Asian females for HDL (P = 0.088). Differences were generally small, but African Americans had the highest mean HDL GRS and lowest mean LDL, triglyceride, and total cholesterol GRS, while East Asians had the lowest mean HDL GRS and highest mean LDL, triglyceride, and total cholesterol GRS ( Table 3) .
Variance explained and conditional SNP impact. The variances explained by the GRSs in GERA using the previously identified lead plus conditional (r 2 < 0.3) SNPs were 16.6%, 18.5%, 16.5%, and 12.9% for HDL, LDL, triglycerides, and total cholesterol, respectively, in non-Hispanic white females and 1.4-2.6% lower in non-Hispanic white males, except that the variance explained for triglycerides was 1.1% higher in males ( Table 5 ). Including the new lead plus conditional SNPs identified in GERA and GERA + GLGC increased variance explained 1.5-3.5% to a total of 18.5%, 20.1%, 18.2%, and 14.4% in non-Hispanic white females. The top ten loci, containing many of the conditional SNPs (included), made up nearly half of the variance explained at 8.7%, 9.8%, 7.5%, and 6.8%, respectively.
Variance explained was different between non-Hispanic whites and the other ancestry groups. Specifically, East Asians (13.9%, females; 14.8%, males) and African Americans (14.7%, females; 13.5%, males) had lower variance explained for HDL, East Asians had dramatically lower values for LDL (6.5%, females; 7.0%, males) and total cholesterol (8.7%, females; 8.0%, males), and African Americans had lower values for triglycerides (8.8%, females; 9.3%, males). These differences may reflect in part the divergence in allele frequencies for SNPs at the same loci in different ancestry groups; we saw an overall trend toward lower MAFs (and thus lower variance explained) in East Asians and African Americans independent of the direction of effect ( Supplementary Fig. 12 ). In addition, mean lipid trait GRSs differed by sex, but less by ancestry group ( Supplementary Table 13 ).
Gain from multiple measurements. We tested the benefit of having multiple lipid measurements in an analysis restricted to individuals with ≥ 5 measurements, using a GRS of the previously identified lead SNPs. Using all measurements, as compared to just one, reduced the standard error of the regression coefficient 15.1% on average over the four traits ( Supplementary Fig. 13 and Supplementary Table 14) ; the regression coefficient estimate itself did not change significantly.
With a large number of measurements, the variance explained by the GRS increased an average of 34% for HDL, LDL, and total cholesterol, but increased more (42%) for triglycerides.
Heritability from all SNPs. Array-based heritability estimates in non-Hispanic whites derived from the genotyped SNPs using PC-Relate kinship estimates 37 , which account for population stratification, and GEAR 38 Table 15 ). Estimates were smaller than those not accounting for population stratification in the kinship estimate, when only adjusting for PC covariates in the phenotype model using GCTA 39 tissue-specific overlap of eQTLs with lipid-associated SNPs. For each tissue, we determined whether the proportion of eQTLs that were lead genome-wide significant SNPs was greater than expected, using a random sampling of SNPs (Methods). Overlap in the liver was significantly greater than the median overlap over all tissues (P = 6.8 × 10 −11 , Bonferroni correction for 44 tissues α = 0.0011; Fig. 2 and Table 2 ). The difference from the median overlap in the pancreas was near Bonferroni significance (P = 0.0014). After excluding any liver eQTL SNPs, the difference from the median overlap in subcutaneous adipose was significant (P = 0.0010; Fig. 2 ). We subsequently stratified the lead genome-wide significant SNPs into three groups: SNPs with P < 1 × 10 −7 for HDL only, LDL only, and triglycerides only. There were no significant tissuespecific eQTL overlaps among the triglycerides-only SNPs. The strongest signal occurred for LDL-only SNPs, for liver (P = 2.7 × 10 −11 ) and pancreas (P = 3.0 × 10 −4 ), with a weaker but significant signal for liver for HDL-only SNPs (P = 6.17 × 10 −5 ) (Fig. 2) . Thus, it appears that the tissue-specific eQTL enrichment in liver and pancreas occurs primarily for LDL-associated variants.
Time to initiation of treatment. We assessed the predictive value of the GRS of each lipid trait, a measure that can be established at birth, for the clinical endpoint of time to initiation of lipid treatment (statins for 90.4% of participants) independent of all other risk factors (Kaplan-Meier curves, Fig. 3 and Supplementary Fig. 14; Cox models, Supplementary Table 16 ). Time to initiation of treatment was most strongly associated with the LDL GRS, with the LDL association stronger in females than in males; the effect of the independent triglyceride GRS in a joint model with LDL GRS was stronger in males than in females (non-Hispanic white females: hazard ratio HR LDL GRS = 2.297, P LDL GRS = 1 × 10 −497 , HR triglyceride GRS = 1.332, P triglyceride GRS = 1 × 10 −38 , concordance index assessing the predictive value of the model = 0.614; non-Hispanic white males: HR LDL GRS = 2.099, P LDL GRS = 1 × 10 −360 , HR triglyceride GRS = 1.398, P triglyceride GRS = 1 × 10 −64 , concordance index = 0.596; test of hazard ratios in females versus males, P LDL = 0.0.00027, P triglycerides = 0.10). The concordance index (sex average = 0.61) showed moderate predictive value 41 . Although the HDL GRS was significantly associated with time to initiation of treatment in a univariate analysis, its significance was greatly diminished and it did not increase the non-Hispanic white concordance index when modeled jointly with triglycerides and LDL. Using a model combining the two GRSs (LDL and triglycerides), for those in the top quintile, the probability of initiating lipid treatment for non-Hispanic white females by age 50 years was 1.66 times higher than that for individuals in the bottom quintile and 1.80 times higher for treatment initiation by age 60 years; in males, the probabilities for individuals in the top quintile were 3.04 and 2.37 times higher, respectively.
Discussion
A large single cohort with clinical-laboratory-based phenotypes from longitudinal EHRs resulted in increased discovery (46 new lead and 15 conditional SNPs in GERA and another 60 SNPs in GERA + GLGC), improved conditional analysis, and allowed a new longitudinal analysis of treatment initiation. Our ancestrally diverse cohort within a single health-provider system elucidated sex and ancestry differences in genetic impact and a substantial prediction (concordance index 0.61) of time to initiation of lipidlowering medication based only on SNP data. We were able to obtain biological insight, demonstrating that lipid-associated SNPs were not only strongly enriched in liver eQTLs but also adipose and pancreas eQTLs.
There was biological support for our new SNPs. Most were associated with gene expression levels in liver and other tissues, and several resulted in amino acid changes, likely impacting protein function. As one example, the nonsynonymous variant rs4149056 (SLCO1B1), associated with triglycerides in GERA + GLGC, was previously reported to be associated with statin-induced myopathy 42 and blood metabolites 43, 44 . SLCO1B1 encodes OATP1B1, which transports various drugs and endogenous ligands 45 , including bile acids 46, 47 , into the liver. In addition, in vivo eQTL analyses of several variants showed an expression effect consistent with the direction of the SNP association. For example, rs2896635[A], associated with higher triglyceride levels in GERA + GLGC, was associated with lower expression of the AHR nuclear-translocatorlike gene (ARTNL, also known as BMAL1), which encodes a core molecular clock component essential for maintaining circadian function 48 . Arntl-knockout mice have increased plasma triglyceride levels 49 with marked differences in triglycerides containing polyunsaturated fatty acids 50 . At some loci, the closest gene was the most biologically plausible. For example, rs7955221, associated with total cholesterol and LDL (GERA + GLGC), is just upstream of NR1H4, which encodes FXR, a bile acid receptor and transcription factor for bile acid synthesis and transport genes 51 . Some loci had more than one biologically plausible candidate and may require functional studies to determine causality. For example, rs13114070, associated with total cholesterol (GERA), is an eQTL for UGT2B17 and UGT2B15 in lymphoblastoid cell lines, with some evidence in GTEx of it acting as an eQTL for UGT2B17 in liver (P = 0.004) 40 . UGT2B15 52 and UGT2B17 encode enzymes that metabolize steroid hormones and a variety of lipidsoluble xenobiotic compounds 53, 54 . Another example, rs10948059, associated with HDL (GERA), is an eQTL for PEX6 and GNMT in numerous tissues. Gnmt-knockout mice have increased serum levels of total and LDL cholesterol 55, 56 and hepatic cholesterol accumulation 55 . In vitro knockdown of peroxisomal protein PEX6 impacts intracellular cholesterol transport, reducing plasma membrane cholesterol and causing lysosomal cholesterol accumulation 57 .
Previous work has suggested that lipid-associated SNPs often code for eQTLs that are expressed in liver tissue; specifically, lipid-associated variants might be primarily associated with functional changes in liver cells 58 . In addition, testing for specific enrichment of associated variants with activity in liver cells in ENCODE-defined regions found the strongest enrichment of GWAS lipid-associated variants in regions with strong enhancer activities 3 . We also found that liver tissue was the strongest outlier in our new eQTL tissue enrichment analysis. However, we noted enrichment in the pancreas for LDL-associated SNPs, which, to our knowledge, has not been previously reported. Although a role for the pancreas in LDL metabolism has not been established, glucagon, a hormone synthesized in pancreatic islet alpha cells, has been reported to decrease intestinal cholesterol absorption 59 . Finding enrichment of eQTLs in subcutaneous adipose tissue was not surprising, as visceral and subcutaneous fat amounts have been associated with plasma lipid levels 60, 61 . However, the GTEx results should be interpreted with some caution due to the very different sample sizes (and hence power) in different tissues.
Our use of a single large cohort allowed for direct conditional analysis, in a cohort much larger than in previous studies 16 , and discovery of 15 additional new SNPs. All conditional SNPs identified were at loci previously identified in other GWAS with very small P values for the lead variants (possibly due to power limitations at other loci). Our requirement of genome-wide significance for conditional SNPs is likely conservative because the prior chance of additional functional SNPs being present in these same regions is high; therefore, we may have underestimated the contribution of these important loci to the total heritability, which may further address the 'missing heritability' question 62 . Many of these loci include genes known to cause Mendelian lipid disorders and have been shown, both historically and recently (exome sequencing), to harbor rare, high-impact mutations 63 Supplementary Fig. 14. The shaded areas represent the 95% confidence intervals around the estimated curves. All tests were two-sided.
We demonstrated a global difference in SNP effects between sexes. While significant differences occurred in both directions, the majority of variants favored a larger effect in females for HDL, LDL, and total cholesterol, mirroring a similar phenomenon recently reported for blood pressure 24 ; this finding is also consistent with higher overall heritability of these traits in females than in males. In contrast, males had higher triglyceride effect sizes and variance explained. While overall SNP effects were greater in females, there was a general lack of consistent directionality of effect. Thus, female -male mean differences in GRSs were small and inconsistent with mean differences in observed traits. Specifically, the mean difference between non-Hispanic white females and males in the GRS was 1.34, 1.58, -0.59, and 1.54 for HDL, LDL, triglycerides, and total cholesterol, respectively, as compared to a large increase in mean HDL and decrease in LDL and triglycerides in females versus males. Thus, it is unlikely that these SNPs contribute in any significant way to the observed mean trait differences between the sexes.
Another advantage of our analysis was having multiple ancestry groups within the same cohort; notably, we saw substantial replication of variants previously identified in groups other than non-Hispanic whites. The HDL and total cholesterol GRSs tracked closest with covariate-adjusted lipid comparisons, with African Americans having the highest HDL GRS and covariate-adjusted mean HDL and South Asians and East Asians having values toward the lower end of the range for both the HDL GRS and measured HDL. Triglycerides showed a similar pattern, with East Asians, Latinos, and South Asians having higher triglyceride GRSs and measured triglycerides than non-Hispanic whites. There was more contrast in LDL, with African Americans having the highest covariate-adjusted LDL but the lowest GRS. Additionally, when testing replication of SNPs previously identified in groups other than non-Hispanic whites, we generally found that the meta-analysis of all GERA groups provided consistent evidence of replication and performed better than using the much smaller ancestry-matched group. In the GERA metaanalysis, 2 of 2 lead SNPs first identified in African Americans 7, 12 replicated, as well as 4 of 5 SNPs identified in Japanese 11 and Chinese 64 and 26 of 34 SNPs identified in Mexicans 10 /Hispanics 5 .
Using a single large cohort allowed us to comprehensively examine dominance and epistasis among the discovered SNPs, the latter of which was not previously possible with summary statistics. While we found modest overall evidence, we discovered one striking example of dominance and epistasis between ABO and FUT2 (secretor). Epistasis between these loci has previously been documented for blood group presentation, but never before for LDL, although each locus has individually previously been associated with LDL. While it is highly likely that secretor status is the causal variant at FUT2, the ABO causal SNP(s) were more challenging to determine given strong regional LD. We also had strong evidence of dominance for the APOE ϵ 2 allele, due to the well-known association of ϵ 2 homozygosity with type 3 hyperlipoproteinemia and elevated triglyceride levels.
We saw a modest increase in variance explained from our enhanced discovery. The overall variance explained by the genome-wide significant loci ranged from 14.4-20.1% in non-Hispanic whites, slightly larger than the values previously reported, which were 9.3-18.8% in 5,119 Finnish 16 and 12-14% in 7,132 Framingham individuals 3 . We used the same cohort for discovery and testing, which may have slightly inflated our estimates. Our array-based heritability estimates ranged from 17.2-27.1%, similar to the 19-27% in the Finnish population. The variance explained by genome-wide significant loci for LDL is very close to the array-based estimate; the variance explained was 4% lower for SNPs were conditioned on all other previously identified SNPs in the region ( Supplementary Table 8 ). SNPs are additively coded according to the number of alleles of that first mentioned in the Alleles column so that the effect size is positive (change per additional lipid-increasing allele in LDL, HDL, triglycerides (TG), or total cholesterol (TC) transformed to a standard normal distribution). SNPs are marked by whether they have r 2 > 0.8 ( ‡), 0.8 ≥ r 2 > 0.5 ( †), or 0.5 ≥ r 2 > 0.3 (*) in European-ancestry individuals with the SNP tested in companion papers published online 65, 66 after completion of our analysis and while the paper was under review. a Terms in parentheses indicate the following: i, the variant is in an intron; e, the variant is in an exon; 3′ , the variant is 3′ of the gene; 5′ , the variant is 5′ of the gene. b Terms in parentheses indicate the following: c, closest gene; v, liver eQTL; p, pancreas eQTL; a, adipose eQTL; o, eQTL in other tissues; + , additional eQTL genes; m, missense variant. c GERA heterogeneity P value. d Conditional meta-analysis effect size. e Conditional meta-analysis P value.
genome-wide significant loci versus array-based heritability for total cholesterol and ~10% lower for both HDL and triglycerides. Thus, much of the genetic variance in LDL currently attributed to GWAS arrays is explained by the currently identified variants, with slightly less so explained for total cholesterol. Neither dominance nor epistasis had measureable overall statistical impact on variance explained. The variance explained for LDL was substantially less in East Asians (less than half of that in non-Hispanic whites or Latinos) and was also lower in African Americans; variance explained for other lipids was also reduced (but less so) in East Asians and African Americans. The likely explanation for this is an ascertainment bias in which the associated variants were predominantly detected in European cohorts, with a bias toward common variants due to power, and these variants tend to have lower MAFs in East Asians and African Americans. This would explain why the difference is seen predominantly in the variance explained (which depends on allele frequencies but in a non-directional way), unlike the mean GRSs, which did not show strong differences among the ancestry groups.
Longitudinal data, including full EHR pharmacy prescription information, allowed us to identify a striking LDL GRS effect and independent triglyceride GRS effect on the initiation of lipid-lowering treatment. Because genetic information could be available decades prior (i.e., at birth) to the development of substantial risk for coronary heart disease and other adverse clinical endpoints, this information could provide a useful baseline estimate for clinical applications targeting high-risk individuals for screening regarding use of lipid-lowering medications and lifestyle modifications. However, guidelines for statins and other lipid-lowering medication use have changed over the past 16 years, and so GRS evaluation will need to account for those factors. While we captured several lower-frequency variants, a wellknown GWAS limitation is testing very rare variants, which have been implicated in lipid changes 63 . However, larger reference samples will enhance rare variant imputation.
After completion of our analysis, two additional large-scale exome-wide lipid analyses were published online as companion papers 65, 66 , including hundreds of thousands of individuals. The first reported 444 variants at 240 loci 65 , with 26 additional variants in the second study 66 . Using a broad definition of overlap (r 2 > 0.3 in 1000 Genomes Project European-ancestry individuals; a handful of nearby variants were not in reference panels and could not be examined, but these were generally very rare), 26 of these variants overlapped with our 121 new variant associations (12 lead variants and 1 conditional variant from GERA and 13 variants from GERA + GLGC). These studies, along with ours, demonstrate enhanced gene discovery from expanded sample sizes.
In summary, our results demonstrate numerous strengths of leveraging large, single cohorts in which longitudinal EHRs with independent measurements are linked to genome-wide data and provide insights into the underlying genetic architecture of plasma lipids to guide future research and clinical care. 
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0064-5.
Replication analysis of loci previously identified. For replication of previously reported loci, we first considered the loci from GLGC 3, 4 , but favoring the refinements from ref. 20 (when exome-wide significant) and refs 16, 18 plus additional new loci from several studies [5] [6] [7] [8] [9] [10] [12] [13] [14] [15] 17 , for a total of 189 loci (defined here as nonoverlapping 1-Mb windows, using the most significant P value for the lead SNP and collapsing 1-Mb windows with r 2 > 0.3, which merged only one window). Of these loci, 185 were available to test. Note that we included genome-wide significant SNPs found in meta-analyses for which results had not yet been tested for replication. We report the proportion of these SNPs that met a Bonferronicorrected significance level for the number of lead SNPs (α = 0.00027) in GERA at the lead GLGC trait, as well as suggestive nominal significance (P ≤ 0.05). We also report on all SNPs previously reported at each locus. SNP and eQTL annotation. SNPs were annotated using GENCODE v13 76 , HaploReg v4.1 77 , and ANNOVAR v2015June17 78 . Individual SNP eQTL associations were determined in GTEx v6 40 , which has genome-wide genotype data imputed to the same reference panel as GERA, in addition to other larger cohorts with data for specific tissues but with genotype data not as closely matched to the SNP data here, including others incorporated into HaploReg 77 : liver eQTLs from the NCBI eQTL Browser 79 , whole blood eQTLs 80 , eQTLs from Europeanand Yoruban-ancestry lymphoblastoid cell lines (LCLs) 81 , and eQTLs in liver and adipose tissue from patients undergoing Roux-en-Y gastric bypass (RYGB) 82 .
Testing for dominance. We tested for dominance deviation from additivity in the previously and newly identified lead and conditional SNPs that were genome-wide significant in GERA or GERA + GLGC (for each trait) and had MAF > 0.05 (for power reasons) by fitting a linear model similar to above, with an additive term for the genotype plus an additional term for dominance, coded as 1 for the two homozygous genotypes and -2 for the heterozygous genotype. Statistical testing was based on the dominance term. Bonferroni corrected significance thresholds for 130, 97, 98, and 132 SNPs associated with HDL, LDL, triglycerides, and total cholesterol, respectively, were 0.00038, 0.00052, 0.00051, and 0.00038.
Testing for epistasis. We tested epistasis by looking at all pairwise sets of previously and newly identified lead and conditional SNPs that were genome-wide significant in GERA or GERA + GLGC (for each trait). For each pair of SNPs, we tested epistasis by fitting a linear model similar to above, with a coefficient for both genotypes (each coded additively) plus an interaction term for the two, which formed the basis for the statistical test. Bonferroni corrected significance thresholds for all 11,026, 6,105, 6,555, and 11,026 pairwise interactions of the 149, 111, 115, and 149 associated SNPs were 4.5 × 10 −6 , 8.1 × 10 −6 , 7.6 × 10 −6 , and 4.5 × 10 −6 , respectively. We confirmed any interactions that were still significant when also modeled with a coefficient for each genotyped allele to also allow for dominance (ABO × FUT2 was actually slightly more significant this way).
To fine-map the ABO-related SNP in the FUT2 interaction, we took best-guess imputed genotypes from the top five associated SNPs, phased them with SHAPEIT, and tested all haplotype pairs with ≥ 50 counts.
Genetic risk scores.
For each lipid trait in GERA, we constructed a GRS for each individual as follows. We performed a multivariate linear regression model within each GERA ancestry group using all SNPs jointly. Then, for each SNP, we performed meta-analysis of the coefficients across ancestry groups. We then constructed the GRS using these coefficients to weight the additive coding of each SNP.
Variance explained. Variance explained was calculated by the R 2 of the GRS according to residuals adjusted for age, sex, and ancestry PCs.
Multiple measures.
To assess the benefit of having multiple lipid measurements, we compared the P values, effect size estimates, and GRS variance explained for the previously described lead GWAS significant SNPs using one, two, three, four, and all measurements from each individual. We used a subset of 34,936 non-Hispanic white individuals, all of whom had at least five lipid measurements available for this analysis, to keep the sample size identical among the comparisons. We also estimated the variance due to measurement error and GRS variance explained in the absence of measurement error by the regression equation (1)
where V k is the variance explained by k measures and the resulting α estimates the inverse of variance explained with no measurement error, as has been described 24 .
GWAS-array-based heritability.
We estimated the additive array-based heritability of each individual's long-term covariate-adjusted average lipid trait using GEAR v0.7.7 38 . Array-based heritability estimates may be more sensitive to artifacts than GWAS results 83 , so we restricted our analysis to the largest group of individuals, non-Hispanic whites, for whom samples were run with the same reagent kit and type of microarray (n = 73,060) 26 . We included only the autosomal data, which is common practice in heritability estimation, and also LD filtered our data so that no two SNPs had pairwise r 2 > 0.8 with a standard greedy algorithm in PLINK v1.07 84 . This resulted in 547,922 genotyped SNPs and 3,796,606 imputed SNPs restricted to r info 2 > 0.8. Because of population stratification, we used PC-Relate v1 37 to estimate kinship coefficients rather than standard GCTA estimates 39 , which assume a homogeneous population; we also compared the results to those obtained using the standard GCTA v1.24.7 kinship estimates with PC adjustment. We used GEAR rather than GCTA to estimate heritability because the PC-Relate kinship estimate matrix was not positive definite; this happens because the matrix entries are computed based on different allele frequencies, i.e., those depending on ancestry using PCs. In all analyses, we removed individuals so that no two remaining individuals had a kinship estimate > 0.025; sample size was maximized using a greedy algorithm in PLINK v1.9 85 , leaving 55,389 individuals.
Tissue eQTL enrichment. We used 44 tissue types with at least 70 samples available from GTEx 40 , which has genome-wide data imputed to the same reference panel used for GERA. We used all lead SNPs from previously and newly identified loci. Next, 200 sets of random frequency-matched (± 0.5%) SNPs (with respect to the lead SNP) were selected, without replacement within each set and excluding all variants within ± 0.5 Mb of all previously and newly identified SNPs. For each tissue, we calculated the proportion of eQTL SNPs that were lead genome-wide significant SNPs to eliminate bias due to varying numbers of eQTLs in each tissue (a reflection of different tissue sample sizes), motivated by, but using a statistic different from, prior studies 24, 86 . An upper-tailed P value for enrichment of the count was calculated with a z score using the overall median tissue proportion and the s.d. of the null distribution of that tissue.
Time to initiation of treatment. Lipid prescription information was derived from the EHRs over the same timeframe as the lipid panels. The large majority of prescriptions were for statins (90.4%), while the remaining prescriptions were for fibrates (3.8%) or other medications (3.3% niacin, 1.7% cholestyramine, 0.6% colestipol, 0.1% ezetimibe, and others totaling altogether < 0.1%). We modeled the time to occurrence of the first prescription as a function of the LDL and triglyceride GRSs (the full 477 lead and conditional previously and newly identified SNPs) via Kaplan-Meier curves for display and Cox proportional-hazards models for hazard ratio inference. Individuals were left-censored at the earliest known EHR or at age 35 years, whichever was later, and right-censored at the latest known EHR. The left censoring was done to allow for an individual's date of entry into Kaiser Permanente or the introduction of EHR data, whichever was later, and right censoring was done to allow for loss to follow-up either due to termination of membership or death. The cutoff at age 35 was chosen because the number of individuals with follow-up time before that age was tiny and caused very poor estimates early in the curve, impacting the later curve. We additionally present the concordance index, measuring the goodness of fit of the model, equal to the area under the receiver operating characteristic (ROC) curve; values closer to 1 (perfect model) indicate better fits than those closer to 0.5 41 .
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary. 
Data exclusions
Describe any data exclusions. The original GERA cohort QC has been described in Kvale et. al.. 2015;  briefly, individuals with DQC score<0.82 and CR<97% were excluded, followed by per package removal of (1) CR<90%, (2) variance ratio <31, (3) sex frequency difference>0.15, (4) overall CR<0.60, (5) poor genotype discordance at an array-specific threshold (>208/851 EUR array, >23/61 EAS array, >8/12 AFR array, >26/71 LAT array). Here, we included all RPGEH GERA cohort individuals who had lipid measurements. We further excluded genotyped variants with poor call rates (CR<90%) and analyzed SNPs that had a count of at least 20. After imputation, we excluded poorly imputed variants with r_info^2<0.8, and a count of at least 20. Finally, we excluded GLGC SNPs with <80,000 subjects.
Replication
Describe whether the experimental findings were reliably reproduced. Two additional cohorts were used for replication.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Participants randomly genotyped.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators blinded.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
